Polyarteritis nodosa pathophysiology: Difference between revisions
Jump to navigation
Jump to search
Sargun Walia (talk | contribs) |
Sargun Walia (talk | contribs) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polyarteritis nodosa}} | {{Polyarteritis nodosa}} | ||
{{CMG}};{{APM}} {{AE}} {{OO}}{{CZ}}; [[User:Haritha|Haritha Machavarapu, M.B.B.S.]] | {{CMG}};{{APM}} {{AE}} {{OO}}{{CZ}}{{SSW}}; [[User:Haritha|Haritha Machavarapu, M.B.B.S.]] | ||
==Overview== | ==Overview== | ||
The exact pathogenesis of PAN is not fully understood.It is a disease of unknown cause that affects [[arteries]], the [[blood vessels]] that carry oxygenated [[blood]] to organs and [[tissues]].PAN affects the medium sized arterial vessels.PAN does not affect large arterial vessels, capillaries, small arterioles and venous system. It occurs when certain [[immune cells]] attack the affected [[arteries]].[[Inflammation]] starts in the vessel [[intima]] and results in [[fibrinoid necrosis]] by destroying the internal and external [[elastic]] [[lamina]].[[Aneurysms]] and [[thrombi]] may develop at the site of [[lesions]].One hypothesis is that this condition is caused by [[antibodies]] against HBV, via a [[Hypersensitivity#Type_3_-_immune_complex | type IIII hypersensitivity reaction]].Due to [[inflammation]] of the medium to small sized [[vessels]] in PAN and the presence of impaired [[endothelial]] function, there could be direct [[endothelial cell]] activation and damage resulting from proinflammatory [[cytokines]] or [[antibodies]] (anti-endothelial cells antibodies).Mutation in CECR1 can lead to vascular and inflammatory disorders which also include PAN. | |||
==Pathophysiology== | ==Pathophysiology== | ||
| Line 30: | Line 31: | ||
===Genetics=== | ===Genetics=== | ||
* The development of PAN is the result of multiple genetic mutations. | |||
** Mutation in CECR1 can lead to vascular and inflammatory disorders which also include PAN.<ref name="pmid24552284">{{cite journal |vauthors=Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CC, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I |title=Early-onset stroke and vasculopathy associated with mutations in ADA2 |journal=N. Engl. J. Med. |volume=370 |issue=10 |pages=911–20 |date=March 2014 |pmid=24552284 |pmc=4193683 |doi=10.1056/NEJMoa1307361 |url=}}</ref> <ref name="pmid24552285">{{cite journal |vauthors=Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, Voth I, Hashkes PJ, Harel L, Hoffer V, Ling E, Yalcinkaya F, Kasapcopur O, Lee MK, Klevit RE, Renbaum P, Weinberg-Shukron A, Sener EF, Schormair B, Zeligson S, Marek-Yagel D, Strom TM, Shohat M, Singer A, Rubinow A, Pras E, Winkelmann J, Tekin M, Anikster Y, King MC, Levy-Lahad E |title=Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy |journal=N. Engl. J. Med. |volume=370 |issue=10 |pages=921–31 |date=March 2014 |pmid=24552285 |doi=10.1056/NEJMoa1307362 |url=}}</ref> | |||
*** CECR1 is also known as ADA2. | |||
*** It is responsible for production of adenosine deaminase 2. | |||
===Associated Conditions=== | ===Associated Conditions=== | ||
The following conditions are associated with the development of polyarteritis nodosa: | The following conditions are associated with the development of polyarteritis nodosa: | ||
*Hepatitis B infection | *Hepatitis B infection | ||
*Hepatitis C infection | *Hepatitis C infection | ||
== Microscopic Pathology == | |||
* Microscopic histopathological analysis of a biopsy sample from a patient of PAN reveals: | |||
** Focal necrotizing arteritis | |||
*** Mixed cellular infiltrate are seen within the vessel wall. | |||
** Nerve biopsy | |||
*** Axonal degeneration | |||
*** Fiber loss | |||
*** Wallerian degeneration | |||
*** Perineural necrosis | |||
*** Neoangiogenesis around epineurium or perineurium | |||
** Segmental demyelination<ref name="pmid11723762">{{cite journal |vauthors=Griffin JW |title=Vasculitic neuropathies |journal=Rheum. Dis. Clin. North Am. |volume=27 |issue=4 |pages=751–60, vi |date=November 2001 |pmid=11723762 |doi= |url=}}</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}}{{WH}} | {{WS}}{{WH}} | ||
Latest revision as of 04:13, 22 May 2018
|
Polyarteritis nodosa Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polyarteritis nodosa pathophysiology On the Web |
|
American Roentgen Ray Society Images of Polyarteritis nodosa pathophysiology |
|
Risk calculators and risk factors for Polyarteritis nodosa pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]Cafer Zorkun, M.D., Ph.D. [4]Sargun Singh Walia M.B.B.S.[5]; Haritha Machavarapu, M.B.B.S.
Overview
The exact pathogenesis of PAN is not fully understood.It is a disease of unknown cause that affects arteries, the blood vessels that carry oxygenated blood to organs and tissues.PAN affects the medium sized arterial vessels.PAN does not affect large arterial vessels, capillaries, small arterioles and venous system. It occurs when certain immune cells attack the affected arteries.Inflammation starts in the vessel intima and results in fibrinoid necrosis by destroying the internal and external elastic lamina.Aneurysms and thrombi may develop at the site of lesions.One hypothesis is that this condition is caused by antibodies against HBV, via a type IIII hypersensitivity reaction.Due to inflammation of the medium to small sized vessels in PAN and the presence of impaired endothelial function, there could be direct endothelial cell activation and damage resulting from proinflammatory cytokines or antibodies (anti-endothelial cells antibodies).Mutation in CECR1 can lead to vascular and inflammatory disorders which also include PAN.
Pathophysiology
Pathogenesis
- Polyarteritis nodosa is a disease of unknown cause that affects arteries, the blood vessels that carry oxygenated blood to organs and tissues.
- PAN affects the medium sized arterial vessels.
- Most commonly occurs at the branching vessels and bifurcation points.
- PAN does not affect:[1]
- Large vessels like aorta.
- Capillaries
- Small arterioles.
- Venous system.
- It occurs when certain immune cells attack the affected arteries.
- Inflammation starts in the vessel intima and results in fibrinoid necrosis by destroying the internal and external elastic lamina.[2]
- Aneurysms and thrombi may develop at the site of lesions.[3]
- The lesion can weaken the vessel and can further can lead to:
- Obstruction
- Ischemia and infarction
- Rupture
- Hemorrhage
- The lesion can weaken the vessel and can further can lead to:
- One hypothesis is that this condition is caused by antibodies against HBV, via a type IIII hypersensitivity reaction.
- Hepatitis C associated polyarteritis nodosa is the most common type among the hepatitis C associated vasculitis and has a severe clinical presentation.[4]
- Clinical responses to immunosuppressive therapy suggest that immunological mechanisms play an active pathogenic role.
- Due to inflammation of the medium to small sized vessels in PAN and the presence of impaired endothelial function, there could be direct endothelial cell activation and damage resulting from proinflammatory cytokines or antibodies (anti-endothelial cells antibodies).
- These anti-endothelial cells antibodies in turn stimulate greater production of cytokines and adhesion molecules potentiating the inflammation causing more damage to the vessels [5].
Genetics
- The development of PAN is the result of multiple genetic mutations.
Associated Conditions
The following conditions are associated with the development of polyarteritis nodosa:
- Hepatitis B infection
- Hepatitis C infection
Microscopic Pathology
- Microscopic histopathological analysis of a biopsy sample from a patient of PAN reveals:
- Focal necrotizing arteritis
- Mixed cellular infiltrate are seen within the vessel wall.
- Nerve biopsy
- Axonal degeneration
- Fiber loss
- Wallerian degeneration
- Perineural necrosis
- Neoangiogenesis around epineurium or perineurium
- Segmental demyelination[8]
- Focal necrotizing arteritis
References
- ↑ Stone JH (October 2002). "Polyarteritis nodosa". JAMA. 288 (13): 1632–9. PMID 12350194.
- ↑ Stone JH (October 2002). "Polyarteritis nodosa". JAMA. 288 (13): 1632–9. PMID 12350194.
- ↑ Colmegna I, Maldonado-Cocco JA (August 2005). "Polyarteritis nodosa revisited". Curr Rheumatol Rep. 7 (4): 288–96. PMID 16045832.
- ↑ Saadoun D, Terrier B, Semoun O; et al. (2011). "Hepatitis C virus-associated polyarteritis nodosa". Arthritis Care Res (Hoboken). 63 (3): 427–35. doi:10.1002/acr.20381. PMID 20981809. Unknown parameter
|month=ignored (help) - ↑ Filer AD, Gardner-Medwin JM, Thambyrajah J, Raza K, Carruthers DM, Stevens RJ; et al. (2003). "Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa". Ann Rheum Dis. 62 (2): 162–7. PMC 1754444. PMID 12525387.
- ↑ Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CC, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I (March 2014). "Early-onset stroke and vasculopathy associated with mutations in ADA2". N. Engl. J. Med. 370 (10): 911–20. doi:10.1056/NEJMoa1307361. PMC 4193683. PMID 24552284.
- ↑ Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, Voth I, Hashkes PJ, Harel L, Hoffer V, Ling E, Yalcinkaya F, Kasapcopur O, Lee MK, Klevit RE, Renbaum P, Weinberg-Shukron A, Sener EF, Schormair B, Zeligson S, Marek-Yagel D, Strom TM, Shohat M, Singer A, Rubinow A, Pras E, Winkelmann J, Tekin M, Anikster Y, King MC, Levy-Lahad E (March 2014). "Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy". N. Engl. J. Med. 370 (10): 921–31. doi:10.1056/NEJMoa1307362. PMID 24552285.
- ↑ Griffin JW (November 2001). "Vasculitic neuropathies". Rheum. Dis. Clin. North Am. 27 (4): 751–60, vi. PMID 11723762.